1. Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer
   Marina C Garassino et al, 2021, Future Oncology CrossRef
2. Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma
   Ah Ra Jung et al, 2020, Scientific Reports CrossRef
3. Epithelial-to-Mesenchymal Transition in the Light of Plasticity and Hybrid E/M States
   Laura Bornes et al, 2021, Journal of Clinical Medicine CrossRef
4. Clinical Impact of the Epithelial-Mesenchymal Transition in Lung Cancer as a Biomarker Assisting in Therapeutic Decisions
   Julien Ancel et al, 2022, Cells Tissues Organs CrossRef
5. Curative-Intent Treatment with Durvalumab in Early-Stage Cancers
   Giovanni Melillo et al, 2021, Advances in Therapy CrossRef
6. Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives
   Eugenia Cella et al, 2022, Expert Opinion on Biological Therapy CrossRef
7. Clinicopathological analysis of a superior sulcus tumor treated by salvage surgery after concurrent definitive chemoradiotherapy followed by durvalumab: A case report
   Soichiro Funaki et al, 2022, Thoracic Cancer CrossRef
8. Epithelial–mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?
   Jente van Staalduinen et al, 2018, Oncogene CrossRef
9. Tobacco extracts promote PD‐L1 expression and enhance malignant biological differences via mTOR in gefitinib‐resistant cell lines
   Fengqi Xiao et al, 2020, Thoracic Cancer CrossRef
10. Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment
    Ze-Long Liu et al, 2021, Therapeutic Advances in Medical Oncology CrossRef
11. TGFβ biology in cancer progression and immunotherapy
    Rik Derynck et al, 2021, Nature Reviews Clinical Oncology CrossRef
12. Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer
    Neal S. McCall et al, 2018, Clinical Cancer Research CrossRef
13. WITHDRAWN: Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns
    Alexandra Frelau et al, 2018, Bulletin du Cancer CrossRef
14. The prognostic impact of programmed cell death 1 and its ligand and the correlation with epithelial-mesenchymal transition in thymic carcinoma
    Soichiro Funaki et al, 2019, Cancer Medicine CrossRef
15. Tests immunohistochimiques PD-L1 dans les cancers du poumon non à petites cellules : recommandations par le groupe PATTERN de pathologistes thoraciques
    Sylvie Lantuejoul et al, 2018, Annales de Pathologie CrossRef
16. Extrafollicular Plasmablasts Present in the Acute Phase of Infections Express High Levels of PD-L1 and Are Able to Limit T Cell Response
    Melisa Gorosito Serrán et al, 2022, Frontiers in Immunology CrossRef
17. Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns
    Alexandra Frelau et al, 2018, Bulletin du Cancer CrossRef
18. TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma
    Ritu Shrestha et al, 2020, Molecular Medicine Reports CrossRef
19. Autocrine TGF-β in Cancer: Review of the Literature and Caveats in Experimental Analysis
    Hendrik Ungefroren, 2021, International Journal of Molecular Sciences CrossRef
20. Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer
    Zhu Lingling et al, 2020, Pathology - Research and Practice CrossRef
21. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
    Corinne Faivre-Finn et al, 2021, Lung Cancer CrossRef
22. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma
    Alexander A. Strait et al, 2021, Communications Biology CrossRef
23. The effects of chemotherapeutic drugs on PD-L1 gene expression in breast cancer cell lines
    Misagh Majidi et al, 2021, Medical Oncology CrossRef
24. The Kraken Wakes: induced EMT as a driver of tumour aggression and poor outcome
    Andrew D. Redfern et al, 2018, Clinical & Experimental Metastasis CrossRef
25. Epithelial‑mesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells
    Ying Wang et al, 2019, Molecular Medicine Reports CrossRef